Get the Stockscreener App
41.01
2.07%
0.83
After Hours:
40.81
-0.20
-0.49%
Nanobiotix Adr stock is traded at $41.01, with a volume of 54,866.
It is up +2.07% in the last 24 hours and up +27.38% over the past month.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
See More
Previous Close:
$40.18
Open:
$42.5
24h Volume:
54,866
Relative Volume:
0.73
Market Cap:
$1.99B
Revenue:
$32.72M
Net Income/Loss:
$-27.55M
P/E Ratio:
-71.72
EPS:
-0.5718
Net Cash Flow:
$-41.40M
1W Performance:
-20.37%
1M Performance:
+27.38%
6M Performance:
+95.94%
1Y Performance:
+1,021%
1-Day Range:
$40.81
$42.88
1-Week Range:
$38.89
$51.03
52-Week Range:
$3.81
$57.14
Nanobiotix Adr Stock (NBTX) Company Profile
Compare NBTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
41.01 | 1.95B | 32.72M | -27.55M | -41.40M | -0.5718 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-26 | Initiated | TD Cowen | Buy |
| Aug-28-24 | Initiated | Guggenheim | Buy |
| Dec-08-23 | Initiated | Leerink Partners | Outperform |
| Jan-06-21 | Initiated | Evercore ISI | Outperform |
Nanobiotix Adr Stock (NBTX) Latest News
NBTX Stock Price, Quote & Chart | NANOBIOTIX SAADR (NASDAQ:NBTX) - ChartMill
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering - GlobeNewswire Inc.
XP posts downbeat Q1 earnings, joins Akamai Technologies and other big stocks moving lower in Tuesday's pre-market session - MSN
XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's P - Benzinga
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer - ChartMill
Nanobiotix (NASDAQ:NBTX) Hits New 1-Year HighHere's What Happened - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap UpStill a Buy? - MarketBeat
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - ChartMill
NBTX Forecast, Price Target & Analyst Ratings | NANOBIOTIX SAADR (NASDAQ:NBTX) - ChartMill
Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Nanobiotix (NASDAQ:NBTX) Trading 7.2% HigherShould You Buy? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap DownHere's What Happened - MarketBeat
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - ChartMill
Nanobiotix H2 Earnings Call Highlights - Yahoo Finance
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 - ChartMill
NANOBIOTIX Statement Regarding Recent Media Speculation - ChartMill
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Benzinga
Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Nanobiotix (NASDAQ:NBTX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Nanobiotix (NASDAQ:NBTX) Sets New 52-Week HighWhat's Next? - MarketBeat
Short Interest in Nanobiotix S.A.Sponsored ADR (NASDAQ:NBTX) Grows By 114.9% - MarketBeat
NANOBIOTIX to Participate in Investor Conferences in March - ChartMill
Nanobiotix (NASDAQ:NBTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap Up Following Analyst Upgrade - Defense World
Nanobiotix (NASDAQ:NBTX) Shares Gap Up After Analyst Upgrade - MarketBeat
Nanobiotix (NASDAQ:NBTX) Stock Price Up 5.8% – Here’s What Happened - Defense World
Nanobiotix (NASDAQ:NBTX) Shares Up 5.8%Should You Buy? - MarketBeat
Looking Into Nanobiotix SA's Recent Short Interest - Sahm
Nanobiotix (NASDAQ:NBTX) Stock Price Down 6.2%Here's What Happened - MarketBeat
Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s Why - Defense World
Nanobiotix (NASDAQ:NBTX) Trading Up 3.3% – Time to Buy? - Defense World
Nanobiotix Adr Stock (NBTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):